CO5680440A2 - COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED - Google Patents
COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USEDInfo
- Publication number
- CO5680440A2 CO5680440A2 CO05003060A CO05003060A CO5680440A2 CO 5680440 A2 CO5680440 A2 CO 5680440A2 CO 05003060 A CO05003060 A CO 05003060A CO 05003060 A CO05003060 A CO 05003060A CO 5680440 A2 CO5680440 A2 CO 5680440A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorder
- disorders
- serotonin reuptake
- anxiety
- pharmaceutical composition
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Uso de un compuesto, que es un inhibidor de recaptación de serotonina, y otro compuesto, que es un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica para el tratamiento de la depresión, trastornos de ansiedad y otros trastornos afectivos, tales como trastorno de ansiedad generalizada, pánico/ansiedad, trastorno obsesivo compulsivo, trastorno de estrés agudo, trastorno de estrés postraumático y trastorno de ansiedad social, trastornos alimentarios tales como bulimia, anorexia y obesidad, fobias, distimia, síndrome premenstrual, trastornos cognitivos, trastornos de control del impulso, trastorno de déficit de atención/hiperactividad, abuso de fármacos o cualquier otro trastorno que responda a inhibidores de recaptación de serotonina.2.- Uso de un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica para utilizarse en combinación con un inhibidor de recaptación de serotonina.3.- Uso de un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica útil para aumentar y/o proveer un comienzo más rápido del efecto terapéutico de un inhibidor de recaptación de serotonina.1.- Use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for the treatment of depression, disorders of anxiety and other affective disorders, such as generalized anxiety disorder, panic / anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia , premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit / hyperactivity disorder, drug abuse or any other disorder that responds to serotonin reuptake inhibitors.2.- Use of a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for use in combination with a serotonin reuptake inhibitor. 3.- Use of a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition useful for increasing and / or providing a faster onset of the therapeutic effect of an inhibitor of serotonin reuptake.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200943 | 2002-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5680440A2 true CO5680440A2 (en) | 2006-09-29 |
Family
ID=36701304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05003060A CO5680440A2 (en) | 2002-06-20 | 2005-01-17 | COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED |
Country Status (8)
| Country | Link |
|---|---|
| CN (1) | CN101358379A (en) |
| AR (1) | AR039723A1 (en) |
| CO (1) | CO5680440A2 (en) |
| EA (1) | EA200401468A1 (en) |
| IS (1) | IS2444B (en) |
| SI (1) | SI1545552T1 (en) |
| UA (1) | UA81248C2 (en) |
| ZA (1) | ZA200409278B (en) |
-
2003
- 2003-06-19 UA UA20041210013A patent/UA81248C2/en unknown
- 2003-06-19 SI SI200330816T patent/SI1545552T1/en unknown
- 2003-06-19 CN CNA2008102158847A patent/CN101358379A/en active Pending
- 2003-06-19 EA EA200401468A patent/EA200401468A1/en unknown
- 2003-06-20 AR ARP030102208A patent/AR039723A1/en not_active Application Discontinuation
-
2004
- 2004-11-18 ZA ZA200409278A patent/ZA200409278B/en unknown
- 2004-11-26 IS IS7557A patent/IS2444B/en unknown
-
2005
- 2005-01-17 CO CO05003060A patent/CO5680440A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1545552T1 (en) | 2007-08-31 |
| IS7557A (en) | 2004-11-26 |
| IS2444B (en) | 2008-11-15 |
| ZA200409278B (en) | 2006-04-26 |
| EA200401468A1 (en) | 2005-04-28 |
| CN101358379A (en) | 2009-02-04 |
| UA81248C2 (en) | 2007-12-25 |
| AR039723A1 (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124111T1 (en) | GLUTAMATE REGULATORS IN THE TREATMENT OF MENTAL DISORDERS | |
| CL2008002916A1 (en) | Compounds derived from triazolopyridine, 11-beta-hydroxysteroid dehydrogenase type I inhibitors; pharmaceutical composition comprising them; and its use in the treatment and / or prevention of diabetes, dyslipidemia, obesity, among others. | |
| NO20055208L (en) | 4- (2-Phenylsulfanyl-phenyl) -piperidine derivatives as serotonin reuptake inhibitors | |
| UY28945A1 (en) | PIRROLOPIRIDINE DERIVATIVES | |
| CO6640335A2 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes | |
| DE60200492D1 (en) | Combination of an inhibitor of serotonin reuptake and an atypical antipsychotic for the treatment of depression, obsessive compulsive disorder and psychosis | |
| EA200801488A1 (en) | SUBSTITUTED PHENETHYLAMINES OWNING SEROTONINERGIC AND / OR NOREPINEFININERGIC ACTIVITY | |
| AR033308A1 (en) | USE OF ENANTIOMERICALLY PURE SCITALOPRAM | |
| RU2012152922A (en) | TREATMENT OF PSYCHOLOGICAL CONDITIONS WITH THE USE OF M1-MUSCARINE RECEPTOR ANTAGONISTS | |
| BRPI0617382A2 (en) | METHODS FOR TREATMENT OF A DISORDER OF THE CENTRAL NERVOUS SYSTEM IN A PATIENT, FOR TREATMENT FOR A PATIENT SUFFERING FROM CONDITIONS AND A SEXUAL DYSFUNCTION, AND FOR REDUCING A DELAY IN THERAPEUTIC EFFECTIVENESS FOLLOWING INITIATION OF TREATMENT | |
| BR112023023030A2 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | |
| DK1545552T3 (en) | Combination therapy using a serotin reuptake inhibitor | |
| RU2007140986A (en) | PREVENTIVE OR THERAPEUTIC AGENT AGAINST DEPRESSION OR ANXIETY DISORDER | |
| CO5680440A2 (en) | COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED | |
| AR047715A1 (en) | ANALEPTIC AND ANTDEPRESSIVE COMBINATIONS | |
| NO20063267L (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| CR7271A (en) | NEW MELATONIN-BASED PHARMACEUTICAL FORMULATIONS AND SIMILAR COMPOUNDS FOR USE IN SOUND DISORDERS | |
| AR048134A1 (en) | THE COMBINATION OF AN INHIBITOR OF THE RECOVERY OF SEROTONINE AND AN ANTAGONIST OF THE RECEIVER OF HISTAMINE 3, THE INVESTED AGONIST OR THE PARTIAL AGONIST | |
| AR026371A1 (en) | NEW FORMULATION, USE AND METHOD | |
| BRPI0413587A (en) | Uses of a Glyt-1 Compound and Inhibitor, Pharmaceutical Composition, Kit, and, Disease Treatment Method | |
| MX2011012596A (en) | Methods of enhancing selective serotonin reuptake inhibitor effects in mammals. | |
| AR047716A1 (en) | ANALEPTIC AND ANTIDEPRESSIVE COMBINATIONS | |
| CO5680458A2 (en) | THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENT | |
| EA200801080A1 (en) | STABLE PHARMACEUTICAL MEDICINE FORMS CONTAINING ESCITALOPRAM AND BUPROPION | |
| AR045314A1 (en) | PHARMACEUTICAL COMPOSITIONS OF ANALEPTICS AND ANTIDEPRESSANTS |